Stay updated on Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.

Latest updates to the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page
- Check4 days agoChange DetectedA service alert has been added regarding planned maintenance on July 26th, indicating that most services will be unavailable for over 12 hours starting at 6 AM EDT.SummaryDifference0.7%
- Check11 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a note regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference0.8%
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.6%
- Check33 days agoChange DetectedThe page has updated its content with new dates and a specific study title, while removing older dates and a related study title.SummaryDifference0.6%
- Check40 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
Stay in the know with updates to Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Eribulin in HR+/HER2- MBC Clinical Trial page.